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stratiﬁed our analysis among patients with 2 or more risk factors,
and found that 72% returned to see the physician within the
intervention group compared to 59 % of the control group
(p-value < 0.05). The intervention also produced a signiﬁcant
increase in the percentage of patients who reported they were
conﬁdent about lowering stroke risk with the physician assis-
tance (69% versus 52%, p-value < 0.05). After confounder
adjustment, patients in the intervention group were still 1.8 times
more likely to visit their physicians than patients in the control
group, in multivariate analyses (p < 0.05). CONCLUSION: This
randomized controlled trial illustrates that provision of tele-
phonic intervention is effective in increasing patient visits to the
physician after stroke screening. These results can be used to
maximize the clinical utility of risk factor identiﬁcation in high
risk communities.
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OBJECTIVE: The 14-item Treatment Satisfaction Questionnaire
for Medication Version I (TSQM) is a reliable and valid instru-
ment to assess patients’ satisfaction with medication, providing
scores on four scales—side effects, effectiveness, convenience and
global satisfaction. In naturalistic studies, using the TSQM with
the side effects domain has a potential to interfere with routine
medical care. In this study, an interactive voice response system
(IVRS)-administered abbreviated 9-item TSQM without the ﬁve
items of the side effects domain (TSQM-9) was psychometrically
evaluated among patients taking antihypertensive medication.
METHODS: A total of 396 subjects who self-reported taking a
prescribed antihypertensive medication were recruited from an
online panel. The subjects were asked to complete the TSQM-9
at the start of the study, along with the modiﬁed Morisky scale,
and then again within 7 to 14 days. Psychometric analyses
including conﬁrmatory factor analysis (CFA), Cronbach’s
alpha and intraclass correlation coefﬁcients were conducted.
RESULTS: There was evidence of construct validity of the
TSQM-9 based on the CFA ﬁndings of the observed data
ﬁtting the Decision Balance Model of Treatment Satisfac-
tion even without the side effects domain (Non-normed Fit
Index = 0.9791; Bentler’s Comparative Fit Index = 0.9860).
TSQM-9 domains had good internal consistency as evident from
Cronbach’s alpha values of 0.84 and greater. TSQM-9 domains
also demonstrated good test-retest reliability with high intraclass
correlation coefﬁcients exceeding 0.70. As expected, the
TSQM-9 domains were able to differentiate between individuals
who were high compliers with medication use and those that
were low compliers, with a moderate-to-high effect size (Cohen’s
d ranging from 0.6 to 0.8). There was evidence of convergent
validity with signiﬁcant correlations with the medication adher-
ence scale. CONCLUSION: The IVRS-administered TSQM-9
was found to be a reliable and valid measure to assess treatment
satisfaction in naturalistic study designs, in which there is poten-
tial for the TSQM’s side effects domain to interfere with routine
clinical care.
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OBJECTIVE: To measure the impact of patient targeted educa-
tion designed to inform atorvastatin users of lower cost anti-
hyperlipidemic alternatives after atorvastatin was removed
from their formulary. METHODS: A retrospective case-control
research design was used with case and control groups composed
of clients that implemented the formulary change on January 1,
2006 and had ﬂat 3-tier copayments. Case group members were
enrolled in clients that implemented a targeted communication
strategy and control group members did not. Success was mea-
sured as switching to a formulary antihyperlipidemic on or after
June 30, 2006. Logistic regression models, estimated separately
for retail and home delivery (HD) channels, was used to estimate
the impact of education on the likelihood of switching control-
ling for age, gender, high dose (40 or 80 MG), prior switching,
household median income, non-preferred and generic copayment
differential, and other client-level trend programs (i.e., step
therapy). RESULTS: A total of 201,223 patients in the control
group and 165,758 patients in the case group met the study
inclusion criteria. Controlling for patient and plan covariates,
patients in the case group in retail were 3.48 times more likely
to switch to a preferred statin (95% Conﬁdence Interval
(CI) = 3.38–3.59) compared to control group members. In HD,
the likelihood of switching was 9.82 (95% CI = 9.46–10.20).
This translates into an absolute increase in the switch rates of
14.3 and 29.8 percentage points for patients in retail and HD,
respectively. CONCLUSION: In the context of a formulary
change, targeted member communication and assistance is an
effective means of promoting lower cost formulary alternatives.
Greater conversion in HD may be related to a higher degree of
assistance and outreach within this channel.
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OBJECTIVE: To assess the clinical effectiveness and cost-
effectiveness of low-density-lipoprotein (LDL) apheresis for
treatment of patients with homozygous (HMZ) and heterozy-
gous (HTZ) familial hypercholesterolemia (FH). METHODS:
Seven case series and one retrospective review with heparin-
induced extracorporeal LDL precipitation (HELP) for the treat-
ment of refractory HMZ and HTZ FH published between
January 1998 and May 2007 were included in the analysis.
RESULTS: The mean acute decrease in LDL-C ranged from
53–77% with HELP. The mean chronic decrease in LDL-C
ranged from 9–46% and the increase in HDL-C ranged from
12–27%. The LDL:HDL ratio exceeded target values. There was
a beneﬁcial impact on coronary outcomes demonstrated by a
decrease in Agatston scores and a regression in atherosclerotic
lesions. Adverse events, ranging 2.9–5.1%, were typically mild
and related to vascular access problems. Studies were generally of
low quality however performing controlled studies is not feasible
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